Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-20-000741
Filing Date
2020-09-18
Accepted
2020-09-18 17:12:28
Documents
2
Group Members
ORBIMED ADVISORS ISRAEL II LTDORBIMED CAPITAL GP V LLCORBIMED CAPITAL GP VI LLCORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIPORBIMED ISRAEL GP II, L.P.ORBIMED ISRAEL GP LTD.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss182018_sc13da.htm SC 13D/A 187224
2 JOINT FILING AGREEMENT ss182018_ex9901.htm EX-99.1 15107
  Complete submission text file 0000947871-20-000741.txt   204184
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 500 BOYLSTON STREET 12TH FLOOR BOSTON MA 02116
Business Address 500 BOYLSTON STREET 12TH FLOOR BOSTON MA 02116 617-482-2333
Adicet Bio, Inc. (Subject) CIK: 0001720580 (see all company filings)

EIN.: 813305277 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90283 | Film No.: 201184666
SIC: 2834 Pharmaceutical Preparations